HK1105963A1 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners - Google Patents

Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Info

Publication number
HK1105963A1
HK1105963A1 HK07111188.2A HK07111188A HK1105963A1 HK 1105963 A1 HK1105963 A1 HK 1105963A1 HK 07111188 A HK07111188 A HK 07111188A HK 1105963 A1 HK1105963 A1 HK 1105963A1
Authority
HK
Hong Kong
Prior art keywords
compounds
inhibiting
interaction
methods
binding partners
Prior art date
Application number
HK07111188.2A
Other languages
English (en)
Inventor
Alfredo C Castro
Wei Deng
Kristopher M Depew
Michael A Foley
Christian C Fritz
Evangelinos Asimina T Georges
Michael J Grogan
Nafeeza Hafeez
Edward B Holson
Brian T Hopkins
Nii O Koney
Tao Liu
David A Mann
Lisa A Marcaurelle
Daniel A Snyder
Dennis J Underwood
Andrew A Wylie
Lin-Chen Yu
Linping Zhang
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of HK1105963A1 publication Critical patent/HK1105963A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07111188.2A 2004-06-17 2007-10-17 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners HK1105963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58061604P 2004-06-17 2004-06-17
US65930105P 2005-03-07 2005-03-07
PCT/US2005/021524 WO2006009869A1 (en) 2004-06-17 2005-06-17 Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners

Publications (1)

Publication Number Publication Date
HK1105963A1 true HK1105963A1 (en) 2008-02-29

Family

ID=35335774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07111188.2A HK1105963A1 (en) 2004-06-17 2007-10-17 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Country Status (22)

Country Link
US (1) US7851637B2 (xx)
EP (1) EP1768966B1 (xx)
JP (1) JP5064213B2 (xx)
KR (1) KR101195351B1 (xx)
CN (1) CN101006065B (xx)
AT (1) ATE548359T1 (xx)
AU (1) AU2005265131B2 (xx)
BR (1) BRPI0511070A (xx)
CA (1) CA2570780C (xx)
EC (1) ECSP067099A (xx)
ES (1) ES2382383T3 (xx)
HK (1) HK1105963A1 (xx)
IL (1) IL179904A (xx)
MA (1) MA28702B1 (xx)
MX (1) MXPA06014754A (xx)
NO (1) NO20070324L (xx)
NZ (1) NZ552183A (xx)
PL (1) PL1768966T3 (xx)
PT (1) PT1768966E (xx)
RU (1) RU2416606C2 (xx)
WO (1) WO2006009869A1 (xx)
ZA (1) ZA200610405B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416606C2 (ru) 2004-06-17 2011-04-20 Инфинити Дискавери, Инк. Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
EP1897956A1 (en) * 2006-09-06 2008-03-12 Lonza AG Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase
EP2926827A3 (en) * 2008-02-08 2015-11-04 Aileron Therapeutics, Inc. Therapeutic Peptidomimetic Macrocycles
EP2315751A1 (en) * 2008-06-26 2011-05-04 Amgen Inc. Alkynyl alcohols as kinase inhibitors
CA2733514C (en) * 2008-08-21 2017-10-24 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02642B (me) * 2008-12-05 2017-06-20 Abbvie Inc Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PL2435432T6 (pl) * 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017096301A1 (en) * 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
JP7114478B2 (ja) 2016-03-28 2022-08-08 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) * 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3643012A1 (de) * 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3829594A1 (de) * 1988-09-01 1990-03-15 Bayer Ag Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3926822A1 (de) * 1989-08-14 1991-02-21 Hoechst Ag Peptide mit bradykinin-antagonistischer wirkung
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0527736B1 (de) 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
RU2149871C1 (ru) * 1993-11-24 2000-05-27 Дзе Дюпон Мерк Фармасьютикал Компани Изоксазолины и изоксазолы, способ подавления агрегации тромбоцитов, фармацевтическая композиция, подавляющая агрегацию тромбоцитов
EP0730587B1 (en) * 1993-11-26 1999-12-08 Pfizer Inc. 3-phenyl-2-isoxazolines as antiinflammatory agents
DE69503769T2 (de) 1994-03-09 1998-12-03 Pfizer Inc., New York, N.Y. Isoxazoline verbindung zur hemmung tnf-freigabe
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
IT1283836B1 (it) 1996-08-28 1998-04-30 Viv Int Spa Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
AR015649A1 (es) * 1997-05-07 2001-05-16 Univ Pittsburgh Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
NZ529792A (en) 2001-05-30 2007-04-27 Univ Michigan Small molecule antagonists of Bcl-2 family proteins
US20030119894A1 (en) * 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
RU2416606C2 (ru) 2004-06-17 2011-04-20 Инфинити Дискавери, Инк. Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию

Also Published As

Publication number Publication date
ECSP067099A (es) 2007-04-26
ATE548359T1 (de) 2012-03-15
IL179904A0 (en) 2007-05-15
RU2007101276A (ru) 2008-08-10
CA2570780A1 (en) 2006-01-26
PL1768966T3 (pl) 2012-08-31
NZ552183A (en) 2009-10-30
CN101006065A (zh) 2007-07-25
JP2008503489A (ja) 2008-02-07
US7851637B2 (en) 2010-12-14
JP5064213B2 (ja) 2012-10-31
AU2005265131A1 (en) 2006-01-26
US20060025460A1 (en) 2006-02-02
WO2006009869A1 (en) 2006-01-26
ES2382383T3 (es) 2012-06-07
KR101195351B1 (ko) 2012-10-29
CA2570780C (en) 2013-12-03
IL179904A (en) 2011-11-30
MA28702B1 (fr) 2007-06-01
AU2005265131B2 (en) 2012-02-23
ZA200610405B (en) 2008-03-26
PT1768966E (pt) 2012-05-23
KR20070046068A (ko) 2007-05-02
NO20070324L (no) 2007-03-19
MXPA06014754A (es) 2007-06-22
EP1768966A1 (en) 2007-04-04
BRPI0511070A (pt) 2007-11-27
CN101006065B (zh) 2012-07-11
EP1768966B1 (en) 2012-03-07
RU2416606C2 (ru) 2011-04-20

Similar Documents

Publication Publication Date Title
HK1105963A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MX2009005184A (es) Compuestos y metodos para inhibir la interaccion de las proteinas bcl con agentes aglutinantes.
JO2917B1 (en) Compounds and methods to inhibit the interaction between BCL and binding partners
TNSN08258A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TW200738234A (en) Triazole compounds that modulate HSP90 activity
TW200716624A (en) Compounds for modulating TRPV3 function
WO2007139960A3 (en) Compounds that modulate hsp90 activity and methods for identifying same
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
HK1107700A1 (en) Triazole compounds that modulate hsp90 activity
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139955A3 (en) Triazole compounds that modulate hsp90 activity
SG171682A1 (en) Iap bir domain binding compounds
TW200602029A (en) Inhibitors of IAP
TN2010000169A1 (en) Molecules and methods for modulating complement component
TW200745159A (en) IL-6 binding proteins
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2004058705A3 (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
WO2004060878A3 (en) Inhibitors of phosphatases
TNSN06418A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TW200621265A (en) Composition for treating tumor and/or preventing tumor transfer and recurrence
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
TW200800952A (en) Biaryl compositions and methods for modulating a kinase cascade
UA98927C2 (ru) Антитело или его фрагмент, которое связывается со склеростином

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160617